Moderna's stock has experienced both gains and losses amid changing circumstances and reactions to its mRNA technologies. RFK Jr. has recently cancelled around $500 million worth of contracts for mRNA vaccine projects, drawing criticism from health experts and causing the stocks to suffer a hit. However, Moderna’s mRNA RSV vaccine recently received expanded FDA approval for younger adults, and the Phase III trials of Moderna's flu vaccine outperformed the standard jab. Despite this progress, Moderna has continued to face challenges such as the cancellation of plans for a new mRNA plant in Japan due to an uncertain business environment, as well as a decrease in its 2025 revenue outlook in the U.K. due to vaccine shipment delays. On the brighter side, promising results have been announced from Moderna's flu vaccine trial. Cases surrounding Moderna’s mRNA patents and Moderna's collaboration with IBM to simulate the longest mRNA pattern using quantum computing highlight the complex and innovative nature of the biotech landscape.
Moderna MRNA News Analytics from Fri, 25 Oct 2024 07:00:00 GMT to Sat, 16 Aug 2025 08:55:38 GMT -
Rating -1
- Rumor -6
